Polio Clinical Trial
Official title:
OPV Transmissibility in Communities After Cessation of Routine OPV Immunization
NCT number | NCT02376374 |
Other study ID # | 31546 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2015 |
Est. completion date | March 31, 2019 |
Verified date | May 2019 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators propose to study both inter- and intra-household Oral Polio Vaccine (OPV) transmission in a primarily inactivated-polio vaccine (IPV)-vaccinated community in Mexico. The investigators will enroll 3 distinct clusters of households in a municipality in Orizaba, Veracruz, Mexico prior to the February 2015 National Immunization Week (NIW.) These clusters will be physically separate from one another and differ only in the proportion of OPV-eligible children who will receive OPV during the February 2015 NIW (10%, 30% and 70% vaccinated.) The investigators will look at inter-household and intra-household transmission. The investigators will then determine if epidemiologic (i.e.: degree of contact), anthropometric (i.e.: nutritional status) or clinical covariates (i.e.: IPV/OPV immunization history) are associated with intra-household transmission.
Status | Completed |
Enrollment | 1828 |
Est. completion date | March 31, 2019 |
Est. primary completion date | February 28, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A to 59 Months |
Eligibility |
Inclusion Criteria: - Households with children under the age of 5 who have up-to-date IPV vaccination history and willing to give informed consent and/or assent. Exclusion Criteria: - Unwilling/unable to bring children's IPV vaccination records up-to-date. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Stanford University | Bill and Melinda Gates Foundation, Instituto Nacional de Salud Publica, Mexico |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Inter-household transmission of poliovirus | Feb 2015-May 2015; 4 months | ||
Primary | Intra-household transmission of poliovirus | Feb 2015-May 2015; 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00772369 -
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
|
Phase 4 | |
Completed |
NCT00401531 -
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants
|
Phase 3 | |
Completed |
NCT00254917 -
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
|
Phase 4 | |
Completed |
NCT00772928 -
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
|
Phase 3 | |
Completed |
NCT04576910 -
Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
|
Phase 4 | |
Completed |
NCT04264546 -
Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06114810 -
Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV
|
Phase 4 | |
Completed |
NCT01475539 -
Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
|
Phase 4 | |
Completed |
NCT01244464 -
A Study of the Safety of IMOVAX Polio™ in China
|
Phase 4 | |
Completed |
NCT00255047 -
Safety and Immune Response of Different Pediatric Combination Vaccines.
|
Phase 3 | |
Recruiting |
NCT05850364 -
A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine
|
Phase 3 | |
Completed |
NCT00662870 -
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
|
Phase 3 | |
Completed |
NCT03147560 -
Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants
|
Phase 4 | |
Completed |
NCT05083039 -
Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
|
||
Active, not recruiting |
NCT00932269 -
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease
|
Phase 0 | |
Completed |
NCT03922061 -
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
|
Phase 1 | |
Enrolling by invitation |
NCT03818477 -
Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card
|
||
Completed |
NCT00348387 -
Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
|
Phase 3 | |
Not yet recruiting |
NCT06460545 -
Phase IV Study of Concomitant Administration of the sIPV and HepA
|
Phase 4 | |
Active, not recruiting |
NCT01908114 -
To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
|
Phase 4 |